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Abstract
Background: Karyopherin β1 (Kpnβ1) is the main nuclear import protein involved in the transport of cargoes from
the cytoplasm into the cell nucleus. Previous research has found Kpnβ1 to be significantly overexpressed in cervical
cancer and other cancer tissues, and further studies showed that inhibition of Kpnβ1 expression by siRNA resulted
in cancer cell death, while non-cancer cells were minimally affected. These results suggest that Kpnβ1 has potential
as an anticancer therapeutic target, thus warranting further research into the association between Kpnβ1 expression
and cancer progression. Here, the biological effects associated with Kpnβ1 overexpression were investigated in
order to further elucidate the relationship between Kpnβ1 and the cancer phenotype.
Methods: To evaluate the effect of Kpnβ1 overexpression on cell biology, cell proliferation, cell cycle, cell morphology
and cell adhesion assays were performed. To determine whether Kpnβ1 overexpression influences cell sensitivity to
chemotherapeutic agents like Cisplatin, cell viability assays were performed. Expression levels of key proteins were
analysed by Western blot analysis.
Results: Our data revealed that Kpnβ1 overexpression, above that which was already detected in cancer cells, resulted
in reduced proliferation of cervical cancer cells. Likewise, normal epithelial cells showed reduced proliferation after
Kpnβ1 overxpression. Reduced cancer cell proliferation was associated with a delay in cell cycle progression, as well as
changes in the morphology and adhesion properties of cells. Additionally, Kpnβ1 overexpressing HeLa cells exhibited
increased sensitivity to cisplatin, as shown by decreased cell viability and increased apoptosis, where p53 and p21
inhibition reduced and enhanced cell sensitivity to Cisplatin, respectively.
Conclusions: Overall, our results suggest that a tight balance of Kpnβ1 expression is required for cellular function, and
that perturbation of this balance results in negative effects associated with a variety of biological processes.
Keywords: Karypherin β1, Overexpression, Cancer biology
Background
The Karyopherin protein superfamily consists of a large
number of soluble transport factors that shuttle proteins
and certain RNAs through the nuclear pore complex
(NPC). Karyopherin β1 (Kpnβ1), the primary nuclear
import protein in interphase cells, imports cargoes that
contain a nuclear localisation sequence (NLS) across the
nuclear membrane and into the nucleus [1]. In the clas-
sical nuclear import pathway, recognition of an NLS,
which most commonly consists of a number of clusters
of basic amino acids and is termed the classical NLS
(cNLS), by a Karyopherin α (Kpnα) isoform is required
for Kpnβ1-mediated nuclear import [2, 3]. After Kpnα
binds to the NLS-containing cargo, forming a bridge
between the cargo and Kpnβ1, Kpnβ1 interacts with
nucleoporins (Nups) on the NPC to allow for transfer of
the cargo through the channel. Once in the nucleus,
binding of RanGTP results in dissociation of the trimeric
complex and release of the cargo [4]. Kpnβ1 and Kpnα
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are then recycled back to the cytoplasm for another
round of nuclear import. Alternatively to classical nu-
clear import, some cargoes are able to bind Kpnβ1
directly (independent of Kpnα; non-classical pathway),
or utilise other members of the Karyopherin β family for
their nuclear import.
Studies have shown that in addition to its role as a
nuclear importer, Kpnβ1 has an equally vital set of roles
during mitosis, acting as a negative regulator for various
mitotic processes from spindle assembly and regulation to
nuclear membrane and nuclear pore reformation, where in
most cases it is counter-regulated by the small regulatory
GTPase, Ran [5, 6]. Previous studies have shown that dis-
ruption of Kpnβ1 expression (by loss of endogenous Kpnβ1
through siRNA-mediated knockdown, or transient overex-
pression of Kpnβ1 using plasmid-based transfection), re-
sulted in the appearance of distinct mitotic defects, such as
multipolar spindles, chromosome misalignment, and lag-
ging or mis-segregation of chromosomes in anaphase/telo-
phase [7–9]. These results suggest that a balance of Kpnβ1
expression may be necessary for correct cell functioning.
It has been shown that Kpnβ1 expression is elevated
in cervical cancer tissue, as well as a number of trans-
formed and cancer cell lines, suggesting its association
with the cancer phenotype [10–12] . We previously
showed that inhibition of Kpnβ1 protein expression
leads to cancer cell death via apoptosis [10], and Kuu-
sisto and Jans (2015) showed that faster growing tumour
cells expressing high levels of Kpnβ1 are more
dependent on, or “addicted to”, Kpnβ1 than their
non-transformed counterparts [13]. These results dem-
onstrate that increased expression, and thus activity, of
Kpnβ1 likely plays a role in cancer cell proliferation,
making Kpnβ1 an attractive anticancer therapeutic tar-
get. Interestingly, siRNA-mediated knockdown of Kpnβ1
leaves normal cells relatively unaffected [9, 10]. It is pos-
sible that cancer cells have devised a mechanism to cope
with their increased metabolic and proliferative demands
by enhancing expression of various proteins, among
them Kpnβ1, potentially explaining why depletion of
Kpnβ1 has such negative effects. In contrast, it appears
as if normal cells are less reliant on Kpnβ1 for processes
such as proliferation.
While a number of studies have revealed the importance
of Kpnβ1 in cancer cell survival and proliferation, and de-
scribed its potential as an anticancer target, the precise role
that Kpnβ1 plays in cellular transformation and cancer
progression is largely unclear. In this study, we investigated
the biological effects associated with Kpnβ1 overexpression
in order to further elucidate the relationship between
Kpnβ1 and cancer progression. While it is evident from
previous work that cancer cells require Kpnβ1 for their
proliferation and survival, it is unclear whether overexpres-
sion of Kpnβ1 provides a growth advantage to cancer cells,
or leads to phenotypes associated with cellular transform-
ation. In this study, we show that Kpnβ1 overexpression in
fact leads to negative effects associated with the function-
ing of cervical cancer cells, and thus a precise balance of
Kpnβ1 expression and activity appears to be essential for
the correct functioning of these cells. Disruption of this
balance in either direction has detrimental effects on many
cellular processes.
Methods
Cell lines and cell culture
The human cervical carcinoma cell lines, HeLa (ATCC
CCL-2) and CaSki (ATCC CRL-1550), and normal pri-
mary (ARPE19) (ATCC CRL-2302) and immortalised
(hTERT-RPE-1) (ATCC CRL-4000) epithelial cells were
obtained from the American Type Culture Collection
(ATCC). Cancer cells were cultured in Dulbecco’s Modi-
fied Eagle’s Medium (DMEM), supplemented with penicil-
lin (100 U/ml), streptomycin (100 μg/ml) and 10% Fetal
Calf Serum (FCS) (HiClone, Thermo Scientific, USA).
Normal cells were cultured in DMEM/F12 media, supple-
mented with penicillin, streptomycin and 10% FCS.
hTERT-RPE-1 cells were maintained in the presence of
10 μg/ml Hygromycin B. Cells were incubated at 37 °C in
5% CO2. Cancer cell lines were authenticated by DNA
profiling using the Cell ID system (Promega, USA).
Generation of stable Kpnβ1 overexpressing cell lines
The plasmid used for overexpression of Kpnβ1 (pEFIR-
ES-Kpnβ1-EGFP) was generated by inserting SacI- and
NotI-digested human Kpnβ1-EGFP, released from the plas-
mid pEGFP-Kpnβ1 (kind gift from Patrizia Lavia, Institute
of Molecular Biology and Pathology, National Research
Council of Italy, Rome, Italy) [7], into the pEFIRES plasmid
(kind gift from Yosef Shaul, Weizmann Institute of Science,
Israel) [14]. The pEFIRES plasmid was used in order to
allow for both the Kpnβ1-EGFP fusion gene and the puro-
mycin resistance gene to be transcribed as a single mRNA
transcript. The presence of an internal ribosome entry site
(IRES) upstream of the puromycin resistance gene ensures
that puromycin-resistant clones express high levels of the
recombinant protein, Kpnβ1-EGFP. pEFIRES-EGFP was
used as a control. For the establishment of cells stably
expressing Kpnβ1-EGFP, cells were transfected with the
pEFIRES-EGFP and pEFIRES-Kpnβ1-EGFP constructs
using Genecellin Transfection Reagent (Celtic Molecular
Diagnostics) or TransFectin Lipid Reagent (Bio-Rad), and
thereafter positively transfected cells were selected with
Puromycin (Calbiochem, Merck). Pools of stably trans-
fected cells were maintained in 0.5 μg/ml Puromycin.
Fluorescence microscopy
To analyse EGFP-tagged protein localisation using fluor-
escent microscopy, cells were grown on glass coverslips
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and fixed in 4% paraformaldehyde. Coverslips were
mounted onto glass slides using Mowiol. Images were
captured using the AxioVision 4.7 software (Zeiss, Ober-
kochen, Germany) under 100 x oil immersion.
Western blot analysis
Western Blot analyses were performed using rabbit
anti-Kpnβ1 (H300) (Santa Cruz Biotechnology, sc-11367),
mouse anti-GAPDH (0411) (Santa Cruz Biotechnology,
sc-47724), rabbit anti-GFP (FL) (Santa Cruz Biotechnol-
ogy, sc-8334), rabbit anti-Cyclin A (H-432) (sc-751), rabbit
anti-Cyclin D1 (HD11) (sc-246), rabbit anti-pHisH3
(Ser-10)-R (Santa Cruz Biotechnology, sc-8656), rabbit
anti-Mcl-1 (H-260) (Santa Cruz Biotechnology, sc-20679),
rabbit anti-E-cadherin (H-108) (Santa Cruz Biotechnology,
sc-7870), mouse anti-Vimentin (V-9) (Santa Cruz Biotech-
nology, sc-6260), rabbit anti-PARP1/2 (H-250) (Santa
Cruz Biotechnology, sc-7150), mouse anti-p53 (DakoCyto-
mation, M7001), rabbit anti-p21 (H-164) (Santa Cruz
Biotechnology, sc-756), rabbit anti-γH2AX (Ser-139) (Cell
Signaling, 2577S), and rabbit anti-TFIID (TBP) (N-12)
(Santa Cruz Biotechnology, sc-204) antibodies.
Luciferase assays
To assay for NFAT luciferase activity, cells were trans-
fected with 50 ng GFP-NFAT (Addgene plasmid #24219;
gift of Jerry Crabtree [15]), 50 ng NFAT-luciferase
(Addgene plasmid #10959; gift of Toren Finkel [16]),
and 5 ng pRL-TK (encoding Renilla luciferase; Promega,
USA). To assay for AP-1, NFκB p65 and p53 luciferase
activity, cells were transfected with either 100 ng
AP1-luciferase reporter construct (containing four cop-
ies of the AP-1 binding site; gift of Michael Birrer [17]),
100 ng NFκB p65 luciferase reporter construct (contain-
ing 5 copies of the p65 binding site; Promega, USA) or
100 ng p53-luciferase reporter construct (Addgene plas-
mid #16442; gift of Bert Vogelstein [18]), as well as 5 ng
pRL-TK. For NFκB p65 luciferase assays, cells were
stimulated with 0.5 μM PMA (Sigma-Aldrich, USA) for
3 h, at 24 h post transfection. Luciferase activity was
assayed using the Dual-Luciferase Reporter assay system
(according to the manufacturer’s instructions; Promega,
USA). Luciferase readings measured using the Veritas
microplate luminometer (Promega, USA) were normal-
ised to Renilla luciferase readings.
Trypan blue cell viability assays
To assay for the number of viable cells, cells were trypsi-
nised and incubated with 0.4% Trypan Blue (Merck
Millipore, USA). Viable (white) and non-viable (blue)
cells were counted using a haemocytometer, and the
number of live cells at various time points was recorded.
MTT proliferation assays
To allow for anchorage-independent growth, cells were re-
suspended in 1% methyl cellulose-containing media and
were plated onto Poly (2-hydroxyethyl methacrylate)
(Poly-HEMA) (Sigma-Aldrich, USA) coated 96-well plates.
The number of colonies formed at various time points post
plating were measured using the MTT reagent (according
to the manufacturer’s instructions; Sigma-Aldrich, USA).
Adherent growth as a result of Kpnβ1 overexpression
was determined using the MTT proliferation assay (ac-
cording to the manufacturer’s instructions; Sigma-Aldrich,
USA).
For the analysis of the effect of p53 and p21 inhibition on
Cisplatin-induced cell death, cells were either co-treated
with Pifithrin α (Sigma) and Cisplatin, or transfected with
control or p21 siRNA (Santa Cruz Biotechnology), using
Transfectin (BioRad, USA) transfection reagent, and treated
with Cisplatin 48 h post-transfection. MTT assays were
performed 24 h after Cisplatin treatment.
Cell cycle analysis
Cells were synchronised with 2 mM Thymidine (Sig-
ma-Aldrich, USA), and released into fresh media. Cells
(and floaters) were harvested and fixed in 100% ethanol
overnight. Fixed cells were treated with 50 μg/ml RNase
and stained with propidium iodide. Cell cycle profiles
were analysed using a BD Accuri Flow Cytometer (Beck-
man Coulter, Fullerton, CA, USA). Quantification of the
percentage of cells at different cell cycle stages was per-
formed using the ModFit LT 3.3 software (Verity Soft-
ware House, USA).
Phalloidin staining of F-actin
Cells were fixed and washed twice in 0.04% PBST before
blocking in 1% BSA for 30 min. Actin was labeled with
50 ng/ml Phalloidin-Tetramethylrodamine B isothiocyan-
ate (Phalloidin) (Sigma-Aldrich, USA) in 1% BSA for
30 min at room temperature. Cell nuclei were stained with
100 ng/ml DAPI and coverslips mounted onto glass slides
using Mowiol. Phalloidin images were viewed using the
Zeiss Inverted Fluorescence Microscope under 100 x oil
immersion and images captured using the AxioVision 4.7
software (Zeiss, Germany).
Cell adhesion assays
Cells were plated on uncoated plates and allowed to
adhere for 1 h at 37 °C. Thereafter, the medium was re-
moved from all wells and ‘washed’ cells were rinsed twice
with PBS before fixation of all cells in 0.5 ml fixation solu-
tion (acetic acid/methanol (1:7)) for 5 min followed by
staining with 0.5% crystal violet solution for 2 h at room
temperature. Plates were rinsed in water and left to dry
overnight. The number of cells over various fields of view
were counted using a light microscope and normalized to
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the number of ‘unwashed’ cells, in order to control for
total cells plated.
In vitro scratch wound healing assay
Cells were grown to approximately 90% confluence,
wounded (at time 0 h) using a pipette tip, and treated
with 5 μg/ml Mitomycin C (Sigma). To record scratch
wound closure, images were captured at 0, 3, 6 and 24 h
time points and gap size measured. Each time point was
normalized to the time 0 gap size.
IC50 determination assays
For the determination of drug IC50 values, cells were
treated with varying concentrations of cisplatin for a
period of 48 h, after which the MTT assay was per-
formed (according to the manufacturer’s instructions;
Sigma-Aldrich, USA). IC50 curves were generated using
GraphPad Prism (GraphPad Software Inc., USA).
Nuclear and cytoplasmic protein fractionation
Cells were grown to 80% confluency, trypsinised, and
the cell pellet resuspended in at least 6 volumes harvest
buffer (10 mM HEPES, pH 7.9, 50 mM NaCl, 0.5 M Su-
crose, 0.1 mM EDTA, 0.5% Triton X-100). Lysates were
incubated on ice for 5 min, followed by centrifugation.
The supernatant was kept aside as the cytoplasmic frac-
tion, and the pellet was resuspended in 500 μl buffer A
(10 mM HEPES, pH 7.9, 10 mM KCl, 0.1 mM EDTA,
0.1 mM EGTA). Centrifugation was performed followed
by resuspension of the pellet in 4 volumes buffer C
(10 mM HEPES, pH 7.9, 500 mM NaCl, 0.1 mM EDTA,
0.1 mM EGTA, 0.1% NP40). Samples were vortexed for
15 min, followed by centrifugation, whereupon the
supernatant was kept as the nuclear extract.
Statistical analysis
For all data comparisons, the Student’s t test was per-
formed using Microsoft Excel. Data was presented as the
mean ± SEM. Unless where otherwise stated, experiments
were performed in triplicate or quadruplicate and repeated
at least three independent times. A p value of < 0.05 was
considered statistically significant.
Results
Exogenous Kpnβ1 enhances the nuclear import of known
Kpnβ1 cargoes in cervical cancer cells
HeLa and CaSki cell lines stably expressing
Kpnβ1-EGFP were established to study the effects of
Kpnβ1 overexpression on various biological pheno-
types. To confirm the presence of EGFP and
Kpnβ1-EGFP, cells were visualised using fluorescence
microscopy. HeLa and CaSki cells expressing EGFP
showed diffuse fluorescence that was both cytoplasmic
and nuclear (predominantly nuclear), probably due to
the fact that EGFP is small (~ 32 kDa) and can thus
passively diffuse across the NPC. Cells expressing
Kpnβ1-EGFP showed nuclear and cytoplasmic
localization of exogenous Kpnβ1, as well as a distinct
perinuclear band (Fig. 1a). This correlates with
Kpnβ1’s function as a nuclear transport protein.
Western blot analysis revealed that Kpnβ1-EGFP was
expressed at approximately equivalent levels to that of
endogenous Kpnβ1 in both HeLa and CaSki cells
(Fig. 1b).
To investigate whether overexpression of Kpnβ1 leads
to enhanced Kpnβ1 functionality (i.e. Kpnβ1-mediated
nuclear import), the nuclear activity of various Kpnβ1
cargoes was assayed in HeLa EGFP and Kpnβ1-EGFP
cells. Luciferase assays were performed to assay for nu-
clear activity of Kpnβ1 cargoes NFAT [14], AP-1 [19],
NFκB p65 [20] and p53 [21, 22]. HeLa cells stably ex-
pressing Kpnβ1-EGFP showed a significant increase in
the nuclear activity of NFAT (Fig. 1c), AP-1 (Fig. 1d),
PMA-induced NFκB p65 (Fig. 1e) and p53 (Fig. 1f ),
thereby suggesting that overexpession of Kpnβ1, by ex-
pression of exogenous Kpnβ1-EGFP, leads to increased
nuclear activity of Kpnβ1 cargo proteins.
Overexpression of Kpnβ1 results in reduced proliferation
of cervical cancer and normal epithelial cells
Since high levels of Kpnβ1 are required for cancer cell
survival and proliferation [10], it was anticipated that
overexpression might confer a further growth advantage.
To determine the effect of Kpnβ1 overexpression on cell
proliferation, trypan blue cell viability assays were per-
formed. Interestingly, results revealed that overexpression
of Kpnβ1 resulted in a significant reduction in the number
of adherent HeLa and CaSki cells (Fig. 2a, b). The number
of live cells decreased and minimal dead cells were
observed, suggesting an inhibition of proliferation rather
than induction of cell death. When the effect of Kpnβ1
overexpression on cell proliferation was expanded to look
at cells grown under anchorage-independent conditions, a
similar result was observed; a significant reduction in
proliferation of HeLa and CaSki cells stably expressing
Kpnβ1-EGFP (Fig. 2c, d).
Since fast proliferating cancer cells already display high
levels of Kpnβ1, it was next determined whether normal
epithelial cells transfected with exogenous Kpnβ1 might
display increased proliferation. Surprisingly, Kpnβ1 overex-
pression in the primary and immortalised epithelial cell
lines, ARPE-19 and hTERT-RPE-1, respectively, resulted in
significantly reduced cell proliferation, similar to that ob-
served in the cancer cell lines, even after only modest over-
expression (Fig. 2e, f). These results suggest that Kpnβ1
overexpression alone is not beneficial to cells, and in fact
inhibits cell proliferation.
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Fig. 1 Kpnβ1 localizes to the nucleus and nuclear membrane in cervical cancer cells and enhances the nuclear import of known Kpnβ1 cargoes. a
Immunofluorescence analysis was used to determine GFP expression across the HeLa and CaSki EGFP and Kpnβ1-EGFP stable cell lines. Representative
GFP-Alexa 488 images are shown for each cell line. Enlarged images in the top right-hand corner show perinuclear localization in representative
Kpnβ1-EGFP cells. b Western blot analysis was used to determine endogenous Kpnβ1 (97 kDa) and exogenous Kpnβ1-EGFP (129.7 kDa) expression
levels across the HeLa and CaSki EGFP and Kpnβ1-EGFP cell lines. The first lane represents protein harvested from untransfected cells. GAPDH was
used as a control for loading. c - f Stable expression of Kpnβ1-EGFP in HeLa cells resulted in a significant increase in NFAT (c), AP-1 (d), PMA-stimulated
NFκB p65 (e) and p53 (f) promoter-driven luciferase activity. Results shown represent the mean ± SEM (*p < 0.05)
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Fig. 2 (See legend on next page.)
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Overexpression of Kpnβ1 results a delay in cervical
cancer cell cycle progression
Due to the suppression of cell proliferation upon exogen-
ous Kpnβ1 expression, the effects of Kpnβ1 overexpres-
sion on cell cycle progression were next investigated.
Using FACS analysis, asynchronous cells revealed only
minor changes when Kpnβ1 was overexpressed (data not
shown), but despite this, it was possible that the cell cycle
was being arrested at several phases after Kpnβ1 overex-
pression. Various cell cycle markers in these cells were
thus investigated by western blot analysis. Levels of Cyclin
A, Cyclin D1 and pS10-Histone-H3 (pHisH3), a marker
for cells in mitosis, were all slightly elevated in the HeLa
and CaSki Kpnβ1-EGFP cells (Fig. 3a), suggesting multiple
phases of the cell cycle were affected by Kpnβ1 overex-
pression. To investigate this further, HeLa EGFP and
Kpnβ1-EGFP cells were synchronized to late G1/early S
phase using a thymidine block and harvested at various
time points post release into complete medium. FACS
analysis of synchronized cells revealed that Kpnβ1 overex-
pression resulted in a prolonged delay or progression from
the G1/S block, as Kpnβ1-EGFP expressing cells pro-
gressed through the cell cycle much slower than the EGFP
expressing cells (Fig. 3b). Quantification of the percentage
of HeLa EGFP and Kpnβ1-EGFP cells in each phase of the
cell cycle showed that while 50% of EGFP expressing cells
had exited G1 phase and entered S phase by approxi-
mately 3 h, it took approximately 6 h for the Kpnβ1-EGFP
expressing cells to reach the same stage (see arrows; Fig.
3c and d). These results suggest that Kpnβ1-EGFP ex-
pressing cells show delayed progression through G1/S and
entry into G2/M phase of the cell cycle.
Western blot analysis confirmed that Kpnβ1 overexpres-
sion resulted in a delay in cell cycle progression. After re-
lease from the thymidine block, pS10-Histone-H3
(pHisH3) peaked at 10 h post release in EGFP cells, but
remained low throughout the whole time-course in
Kpnβ1-EGFP cells indicating that the cells did not reach
M-phase within 10 h post release (Fig 3e). Mcl-1 has been
previously shown to increase during S and G2 phase and
peak at mitosis [23], and this same trend was observed in
EGFP cells (for the Mcl-1 long isoform; the short isoform
was not detected). Kpnβ1-EGFP cells, however, showed a
decrease in expression from the baseline levels observed
in asynchronous cells, suggesting that Mcl-1-L may be
downregulated or degraded in response to Kpnβ1 overex-
pression. Interestingly, degradation of Mcl-1 has been
shown to be induced under a number of cell stress condi-
tions [23, 24].
These results support a central role for Kpnβ1 in
regulating the proliferation and cell cycle progression of
cervical cancer cells, such that when its expression is en-
hanced, or inhibited [9, 10, 25], cancer cell proliferation
and cell cycle progression is reduced.
Kpnβ1 overexpression affects cell morphology and actin
reorganization
Due to the negative effects of Kpnβ1 overexpression on
cancer cell proliferation and cell cycle progression, the
effects of Kpnβ1 overexpression on additional biological
phenotypes, including cell morphology and actin
organization, were next analysed. Phase contrast micros-
copy of HeLa and CaSki cells stably overexpressing
Kpnβ1 showed distinct changes in cell morphology, with
cells becoming smaller and more tightly packed (Fig. 4a,
Additional file 1: Figure S1A). Quantification of the
changes in cell area showed that Kpnβ1 overexpression
resulted in a significant decrease in cell area when com-
pared to the area of HeLa and CaSki EGFP cells (Fig. 4b,
Additional file 1: Figure S1B).
Changes in cell morphology are often driven by re-
arrangement of the cytoskeleton; thus immunofluores-
cence actin staining assays were performed using
phalloidin, a high-affinity filamentous actin (F-actin) probe,
to investigate actin reorganization in HeLa and CaSki cells
stably overexpressing Kpnβ1. Phalloidin staining revealed
changes in cell shape, as well as a reduction in the number
of actin-rich cytoplasmic extensions seen at the edges of
the elongated, spindle-shaped control cells, more evident
in HeLa cells (Fig. 4c, Additional file 1: Figure S1C). Quan-
tification of these changes showed that Kpnβ1 overexpres-
sion resulted in a significant decrease in cell area (data not
shown), as well as a significant decrease in the number of
cytoplasmic protrusions (Fig. 4d, Additional file 1: Figure
S1D). This data confirms the changes in cell morphology
and size seen using phase contrast microscopy, and sug-
gests that Kpnβ1 (or the changes associated with overex-
pression of Kpnβ1) plays a role in actin reorganisation.
(See figure on previous page.)
Fig. 2 Overexpression of Kpnβ1 results in reduced proliferation of cervical cancer and normal epithelial cells. a, b Trypan Blue assays revealed a
significant reduction in the number of live HeLa (a) and CaSki (b) cells expressing Kpnβ1-EGFP compared to EGFP. Cells were counted for a period of
up to 4 days post plating. c, d MTT cell proliferation assays reveal a significant reduction in the anchorage-independent proliferation of HeLa (c) and
CaSki (d) cells stably overexpressing Kpnβ1. Cells growing adherently were plated in 1% methylcellulose-containing media into 96-well plates coated
in 12 mg/ml poly-HEMA. Cell proliferation was assayed by the addition of the MTT reagent for a period of up to 8 days. Results shown represent the
mean ± SEM (*p < 0.05). e Western blot analysis reveals moderate Kpnβ1 overexpression in ARPE-19 and hTERT-RPE-1 normal epithelial cell lines. f
Trypan blue assays show a significant reduction in ARPT-19 and hTERT-RPE-1 cell number 96 h after transient Kpnβ1 overexpression. Results shown
represent the mean ± SEM (*p < 0.05)
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Overexpression of Kpnβ1 results in changes in cell
adhesion properties
The observed morphological changes between EGFP and
Kpnβ1-EGFP expressing cells suggests that overexpression
of Kpnβ1 causes cells to pack tighter and form clusters,
which indicates the possibility of tight junction formation
and increased cell adhesion. Thus, to investigate whether
the observed morphological changes were associated with
A B C
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Fig. 3 Overexpression of Kpnβ1 results in a delay in cell cycle progression. a Protein was harvested from HeLa and CaSki EGFP and Kpnβ1-EGFP cells
and cell cycle markers investigated by western blot analysis. Cyclin A, cyclin D1 and pHistoneH3 were all expressed at slightly higher levels in the
overexpressing cells compared to the EGFP control cells. GAPDH was used to control for protein loading. b Flow cytometric analysis of HeLa EGFP and
HeLa Kpnβ1-EGFP cells following synchronization into late G1 and release into S phase. Cells were synchronized with 2 mM thymidine, harvested at
various time points post release and examined by FACS analysis. An asynchronous culture of cells (async) was used for comparison. c and d Line
graphs represent quantification of the percentage of cells in each phase of the cell cycle for EGFP (b) and Kpnβ1-EGFP (c) cells. Arrows represent the
approximate point where 50% cells had exited the G1 phase. Results shown represent the mean ± SD. e Western blot analysis was used to determine
the expression levels of cell cycle associated proteins at various time points post release following thymidine synchronization, in HeLa EGFP and
Kpnβ1-EGFP cells. Protein harvested from an asynchronous culture of cells (a) is shown for comparison. GAPDH was used as a control for loading
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any changes in cell adhesion, adhesion assays using un-
coated cell culture dishes were used to determine overall
changes in the adhesion properties of cells (particularly
those involving cell-surface/cell-substrate interactions).
Results show that HeLa and CaSki cells overexpressing
Kpnβ1 were significantly more adherent compared to
EGFP expressing cells (Fig. 4e, Additional file 1: Figure
S1E). Furthermore, the expression levels of various pro-
teins known to be involved in adhesion, such as
E-cadherin (plays an important role in promoting cell-cell
adhesion [26]), and Vimentin (a marker of mesenchymally
derived, non-adherent cells [27]), were also investigated.
Western blot analysis revealed that E-cadherin levels were
elevated in HeLa and CaSki cells overexpressing Kpnβ1,
while Vimentin levels were decreased (Fig. 4f, Additional
file 1: Figure S1F). To determine whether the altered cell
adhesion properties and EMT protein profiles of
Kpnβ1-EGFP expressing cells might affect cell migration,
a scratch wound healing assay was performed. Interest-
ingly, no change in cell migration was identified in the
Kpnβ1-EGFP compared to control EGFP cells (Fig. 4g, h,
Additional file 1: Figure S1G, H). These results suggest
that dysregulation of Kpnβ1 expression results in altered
processes associated with cell-surface (ie. cell to extracel-
lular matrix) and cell-cell adhesion, but does not affect the
migration capabilities of cervical cancer cells.
Kpnβ1 overexpression sensitizes HeLa cells to cisplatin
treatment
Due to the fact that Kpnβ1 is involved in the nuclear im-
port of proteins involved in apoptosis induced by chemo-
therapy, such as p53 [9, 28, 29], and since overexpression
of Kpnβ1 alters the proliferation and cell cycle progression
of cervical cancer cells, we next investigated whether
Kpnβ1 overexpression may influence the effectiveness of
cisplatin, an anticancer chemotherapy commonly used to
treat patients with cervical cancer. To investigate whether
upregulation of Kpnβ1 could alter the response of cancer
cells to cisplatin treatment, cisplatin IC50 values were com-
pared in HeLa EGFP and Kpnβ1-EGFP cells. The IC50
value for cisplatin was revealed to be 24.9 μM in EGFP
cells and 13 μM in Kpnβ1-EGFP cells, respectively,
suggesting that cells overexpressing Kpnβ1 have increased
sensitivity to cisplatin (Fig. 5A, Additional file 2: Figure S2).
Examination of cell viability confirmed these results; a sig-
nificant decrease in cell viability at various concentrations
of cisplatin was observed in cells expressing Kpnβ1-EGFP
compared to those expressing EGFP (Fig. 5B). To
determine whether the increased sensitivity to cisplatin
treatment observed in cells overexpressing Kpnβ1 was
associated with increased apoptosis, PARP cleavage after
cisplatin treatment in EGFP and Kpnβ1-EGFP cells was
analysed. Western blot analysis revealed enhanced PARP
cleavage in cells overexpressing Kpnβ1 (Kpnβ1-EGFP)
compared to cells expressing EGFP (Fig. 5C), which was
confirmed by densitometric analysis (Fig. 5D). The effect of
Kpnβ1 overexpression on the expression of various
proteins that are known to be involved in the cisplatin re-
sponse was next explored, including p53, p21 and Mcl-1.
Examination of p53, p21 and Mcl-1 expression showed
that cisplatin treatment lead to a concentration-dependent
increase in p53 levels, and a concentration-dependent
decrease in p21 and Mcl-1 levels, evident in both EGFP
and Kpnβ1-EGFP cells but more prominent in the latter
(Fig. 5E). Furthermore, Kpnβ1-EGFP cells showed higher
p53 levels and lower p21 and Mcl-1 levels without cisplatin
treatment (0 μM). As Kpnβ1 overexpression has been re-
ported to cause mitotic abnormalities and induce genomic
instability [7, 8], we investigated the DNA damage marker
γH2AX after cisplatin treatment in Kpnβ1-EGFP
compared to EGFP cells. Western blot analysis revealed
that γH2AX levels were enhanced upon treatment of
Kpnβ1-EGFP cells with cisplatin, indicative of higher levels
of DNA damage in cells overexpressing Kpnβ1 (Fig. 5E).
The upregulation of p53 and downregulation of p21 in
the Kpnβ1-EGFP-overexpressing cells, and in response
to Cisplatin, warranted further investigation as p21 levels
typically follow that of p53. To further explore the role
of these proteins in the cellular response to Cisplatin,
their localisation was examined. While p53 was found to
be predominately nuclear in the EGFP and Kpnβ1-EGFP
cells, p21 displayed more cytoplasmic localisation (Fig.
5F). p53 and p21 were next inhibited, using Pifithrin α
and p21 siRNA respectively, and the effect on Cisplatin
(See figure on previous page.)
Fig. 4 Overexpression of Kpnβ1 results in changes in the morphology and adhesion properties of cervical cancer cells. a Phase contrast images
showing HeLa EGFP and Kpnβ1-EGFP cells, taken 48 h post plating. Cells were viewed at 20 x magnification using the Zeiss Primovert inverted
phase microscope. b Quantification of relative HeLa cell area ± SEM of forty cells from each condition was performed using the AxioVision 4.7
software (*p < 0.05). c Fluorescent staining of polymeric F-actin using phalloidin (red) in EGFP and Kpnβ1-EGFP expressing HeLa cells. DAPI stain
was used to visualize the cell nuclei (blue). d Quantification of the number of cytoplasmic protrusions from the captured fluorescent images.
Results shown represent the mean ± SEM over fifteen fields of view (*p < 0.05). e Relative cell adhesion of HeLa EGFP and Kpnβ1-EGFP cells.
Adherent cells (on uncoated tissue culture plates) were fixed (after removing non-adherent cells by washing) and stained with 0.5% crystal violet
solution. Cells over ten fields of view, viewed at 10 x magnification, were counted using ImageJ and normalized to unwashed cells. Results
shown represent the mean ± SEM (*p < 0.05). f Western blot analysis showing E-cadherin and Vimentin expression in Kpnβ1-overexpressing cells.
GAPDH was used as a control for loading. g An in vitro scratch wound healing assay was performed and showed no change in migration of
HeLa EGFP and Kpnβ1-EGFP cells within a 24 h period. h Quantification of the scratch wound healing assay in G
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responsiveness monitored by MTT. Interestingly, p53 in-
hibition resulted in decreased cell death and p21 inhib-
ition resulted in increased cell death in response to
Cisplatin (Fig. 5G, H). Similar results were obtained using
the CaSki EGFP and Kpnβ1-EGFP cells (Additional file 3:
Figure S3). These results suggest that p53 acts to promote
and p21 protect cells from Cisplatin toxicity. The in-
creased sensitivity of Kpnβ1-EGFP-overexpressing cells to
Cisplatin can thus, in part, be explained by the increased
p53 and decreased p21 levels in these cells.
Discussion
Changes in gene expression patterns are a significant
driver of cancer progression. Thus, the identification of
genes and pathways involved in and/or altered in this
process will not only improve our understanding of cancer
initiation and development, but will also help in the iden-
tification of novel anticancer drug targets. Previous studies
have revealed Karyopherin β1 (Kpnβ1), the primary nu-
clear import protein, to be significantly overexpressed in a
variety of cancer types including cervical [10], gastric [30],
and breast cancers [13]. Furthermore, these studies reveal
that inhibition of Kpnβ1 expression leads to cancer cell
death, while inhibition in non-cancer cells has only a
minor effect on cell viability [10]. These results suggest
that Kpnβ1 has potential as an anticancer therapeutic tar-
get, thus warranting further research into the association
between Kpnβ1 expression and cancer progression.
To better understand the role that Kpnβ1 plays in malig-
nant transformation, we investigated the effects of Kpnβ1
overexpression on various biological processes associated
with cellular transformation. A stable Kpnβ1 overexpress-
ing cell line was generated and shown to result in enhanced
nuclear activity of known Kpnβ1 cargoes. Surprisingly, this
did not translate into an enhanced cancer phenotype as an-
ticipated, but rather suppressed cancer cell proliferation,
delayed cell cycle progression, and altered cell morphology
and actin reorganization, resulting in increased cell adhe-
sion. This suggests that while overexpression of Kpnβ1 is
required for the cancer phenotype, further overexpression
suppresses the malignancy of cervical cancer cells. This
could be due to a number of reasons; such as an imbalance
in nuclear import and export, resulting in altered nuclear
localisation of cargo proteins whose localisation is critical
for cell functioning. Alternatively, upregulation of Kpnβ1
could result in increased nuclear import of tumour sup-
pressor proteins; indeed, it has been found that Kpnβ1
overexpression resulted in an increase in the nuclear activ-
ity of p53, a known Kpnβ1 cargo protein [21, 22]. Overex-
pression of Kpnβ1 may also result in the increased nuclear
import of various other cell cycle proteins that are Kpnβ1
cargoes, such as cyclin B1 and cyclin E [31], whose altered
localisation could greatly impact cell cycle progression.
Interestingly, Kpnβ1 overexpression did not result in an in-
crease in cell death in these cells, therefore the effects seen
were due a reduction in rate of proliferation rather than an
induction of cell death. Ultimately, the nuclear transport
process is a tightly regulated process that is critical for cell
functioning. Altering this process, by increasing the expres-
sion of Kpnβ1 alone, has negative cellular consequences for
cervical cancer cells.
Normal cells overexpressing Kpnβ1 also displayed
reduced cell proliferation, suggesting that Kpnβ1 alone
is insufficient to promote cancer behaviour. In contrast
to our results, Kodama et al. (2017) showed that stable
overexpression of Kpnβ1 in ovarian cancer cells resulted
in a significant increase in cell proliferation, and these
authors suggest that Kpnβ1 acts as an oncogene [32]. It
is possible that the effects observed due to Kpnβ1 over-
expression may be specific to different cell types, and
are likely subject to the levels of endogenous Kpnβ1
present in certain cell lines. Furthermore, while we show
that the overexpressed Kpnβ1 in our study is functional,
in that it results in the increased nuclear activity of
Kpnβ1 cargoes, it is possible that the EGFP tag, fused to
its C-terminus, may alter Kpnβ1 function or its ability to
bind interaction partners, compared to the tag-less
Kpnβ1 overexpressed by Kodama et al. (2017), hence
contribute to the discrepancies between studies.
While Kpnβ1 overexpression alone appears to be
insufficient to induce any of the biological phenotypes
associated with cellular transformation, overexpression
of additional members of the nuclear transport machin-
ery may be required for cancer-associated changes. It is
(See figure on previous page.)
Fig. 5 Cisplatin sensitivity in Kpnβ1 overexpressing cells. A The IC50 value for cisplatin was determined for HeLa EGFP and HeLa Kpnβ1-EGFP cells. B
Cell viability for EGFP and Kpnβ1-EGFP cells was analyzed 48 h after cisplatin treatment via an MTT assay, and results were normalized to the viability
of the untreated cells. Results shown for A and B represent the mean ± SEM (*p < 0.05). C PARP cleavage was analyzed as an indication of apoptosis in
both EGFP and Kpnβ1-EGFP cells 48 h after cisplatin treatment. GAPDH was used as a control for loading. D Densitometric quantification of C-PARP
relative to GAPDH from two independent experiments. E HeLa EGFP and Kpnβ1-EGFP cells were treated with cisplatin for 24 h, followed by western
blot analysis to determine the levels of γH2AX, p53, p21 and Mcl-1. GAPDH was used as a control for loading. F Nuclear and cytoplasmic proteins were
isolated from HeLa EGFP and Kpnβ1-EGFP cells and p53 and p21 levels determined by western blot analysis. TBP and GAPDH were used to control for
even nuclear and cytoplasmic protein loading, respectively. G HeLa EGFP (a) and Kpnβ1-EGFP (b) cells were co-treated with Cisplatin and the p53
inhibitor Pifithrin α, and cell proliferation monitored 24 h later using the MTT assay. H HeLa EGFP (a) and Kpnβ1-EGFP (b) cells were transfected with
control (ctl) or p21 siRNA, and 48 h later treated with Cisplatin for 24 h, whereafter cell proliferation was monitored using the MTT assay. Results shown
represent the mean ± SEM of experiments (*p < 0.05)
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possible that in terms of nuclear import, cancer cells
have already reached their maximum capability and thus
further enhancement of various factors such as Kpnβ1,
without strict control and regulation of all factors
involved in nuclear transport (i.e. a precise balance),
results in further cellular dysfunction.
A wide range of cancer processes have been shown to
rely on Kpnβ1-mediated nuclear import. For example, a
recent review shows how the Karyopherin proteins are
involved in controlling a large number of epithelial-mes-
enchymal transition (EMT) promoting pathways [33].
Kpnβ1 has been shown to be involved in the nuclear
translocation of a number of EMT-promoting proteins
including Snail [34], Smad [35], and Notch [36], all of
which play a role in increasing cancer cell invasion and
metastasis. In addition to this, Kpnβ1 has also been
shown to play a role in actin cytoskeleton regulation, by
regulating the interaction between an actin binding kine-
sin (NabKin) and F-actin, demonstrating that Kpnβ1
likely plays a role in influencing cytoskeletal elements
and structure [6, 37]. We showed that Kpnβ1 overex-
pression resulted in changes in cell morphology and
actin reorganisation, with cells becoming smaller and
more epithelial-like. In addition, Kpnβ1 overexpressing
cells showed enhanced adhesion, as well as an increase
in E-cadherin and decrease in Vimentin protein expres-
sion. These results suggest that overexpression of Kpnβ1
results in a mesenchymal-to-epithelial transition (MET),
where cells transition from motile, more spindle-shaped
mesenchymal cells to adherent, more compact/columnar
epithelial cells. There is much evidence linking the EMT
process with tumour progression and malignant trans-
formation, as transitioning to a more mesenchymal state
promotes cell invasion and metastasis (or cancer cell
dissemination) [38]. More recently, evidence has started
to emerge supporting the concept that MET may be im-
portant for metastatic colonization, but research remains
limited. Thus, it appears that overexpression of Kpnβ1,
beyond that which is already elevated, has negative
consequences for the proliferation, progression and
metastatic potential of cancer cells.
To identify whether overexpression of Kpnβ1 resulted in
any changes to the cancer cell response to cisplatin treat-
ment, HeLa EGFP and Kpnβ1-EGFP cells were treated
with cisplatin and the effects on various processes ob-
served, including cell viability and apoptosis. Our results
revealed that Kpnβ1 overexpressing HeLa cells showed sig-
nificantly reduced viability after treatment with cisplatin,
and were more prone to cisplatin-induced apoptosis when
compared to HeLa EGFP cells. This could be due to
enhanced nuclear import of cargo proteins required for the
apoptotic process, for example p53 [9, 28, 29]. p53 is
involved in the activation of apoptosis induced by
DNA-damaging agents, such as cisplatin [39]. We showed
that HeLa cells overexpressing Kpnβ1 showed higher levels
of p53 when treated with cisplatin, compared to cells ex-
pressing EGFP, and that the same trend in expression was
seen with the DNA damage marker, γH2AX. Examination
of the expression levels of anti-apoptotic proteins p21 and
Mcl-1, revealed that both proteins were reduced in re-
sponse to cisplatin treatment, and the reduction was more
prominent in cells overexpressing Kpnβ1, suggesting that
these cells are more sensitive to apoptotic signals. We also
showed that stable overexpression of Kpnβ1 in synchro-
nized HeLa cells resulted in a decrease in (or degradation
of) Mcl-1 expression. Interestingly, a number of recent
studies have shown that inhibition of Mcl-1 expression
sensitizes cancer cells to cisplatin-induced apoptosis [40,
41]. We show that p21 inhibition sensitises cervical cancer
cells to cisplatin treatment, which is in agreement with
other studies showing that knockdown or inhibition of p21
expression significantly increases apoptosis of ovarian can-
cer and testicular cancer cells induced by cisplatin [42, 43].
On the other hand, other studies have reported p21 over-
expression to increase Cisplatin sensitivity in lung adeno-
carcinoma cells [44, 45] and osteosarcoma cells [46], thus
it is clear that different cancer cells use different cellular
mechanisms to govern Cisplatin responsiveness. We also
show that despite the HPV positive nature of HeLa and
CaSki cells (and thus low p53 activity), p53 inhibition
reduces cervical cancer cell sensitivity to Cisplatin, suggest-
ing a role for p53 in mediating Cisplatin-induced cell
death. This is corroborated by other studies, which show a
role for p53 in Cisplatin-induced apoptosis [47]. However,
p53, like p21, can exert anti-apoptotic effects in response to
Cisplatin in other contexts [48]. Taken together, in our
study, p53 and p21 enhance and protect cervical cancer
cells from Cisplatin-induced cell death, respectively, thus
the higher p53 and lower p21 in the Kpnβ1-EGFP-overex-
pressing cells likely contributes, at least in part, to the in-
creased sensitivity of these cells to Cisplatin. Interestingly,
Kodama et al. (2017) recently showed that inhibition of
Kpnβ1 expression, in combination with paclitaxel treat-
ment, synergistically reduced cell proliferation/viability in
ovarian cancer cells [32].
Whilst we have previously shown that Kpnβ1 inhib-
ition, genetically or pharmacologically, resulted in an in-
duction of cervical cancer cell death and the appearance
of mitotic defects [9, 10, 25], others have reported that
exogenously expressed Kpnβ1 induced mitotic abnor-
malities, resulting in genomic instability [7, 8]. We re-
port that Kpnβ1 overexpression results in increased
levels of pSer10 Histone H3 in asynchronous cells, and
delays cell cycle progression into G2/M in cells released
from a thymidine block, suggesting that mitotic pro-
cesses are somewhat impaired in these cells. However,
further overexpression of Kpnβ1-EGFP, beyond that
achieved in this study, resulted in distinct mitotic defects
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and cell death (data not shown), further reinforcing that
Kpnβ1 overexpression is detrimental to cervical cancer
cell biology. It is likely that cancer cells require a precise
balance of Kpnβ1 expression, and that perturbation of
this balance in either direction has deleterious effects on
cancer cell survival.
Conclusion
To our knowledge this is the first study to show that
overexpression of Kpnβ1 provides no growth advan-
tage to cervical cancer cells or non-cancer epithelial
cells. In fact, when Kpnβ1 is overexpressed in cervical
cancer cells, negative effects associated with a variety
of biological processes are observed, including re-
duced cell proliferation, delayed cell cycle progression,
altered cellular morphology, and increased cellular ad-
hesion. Furthermore, Kpnβ1 overexpression enhances
cervical cancer cell sensitivity to cisplatin, mediated
via increased p53 and decreased p21 protein levels.
Ultimately, it appears as if a tight regulation of Kpnβ1
is essential for the correct functioning of cancer cells
and for the responsiveness of these cells to chemo-
therapeutic agents, like Cisplatin.
Additional files
Additional file 1: Figure S1. Overexpression of Kpnβ1 results in
changes in the morphology and adhesion properties of CaSki cervical
cancer cells. A: Phase contrast images showing CaSki EGFP and Kpnβ1-
EGFP cells, taken 48 h post plating. Cells were viewed at 20 x magnifica-
tion using the Zeiss Primovert inverted phase microscope. B: Quantifica-
tion of relative CaSki cell area ± SEM of forty cells from each condition
was performed using the AxioVision 4.7 software (*p < 0.05). C: Fluores-
cent staining of polymeric F-actin using phalloidin (red) in EGFP and
Kpnβ1-EGFP expressing CaSki cells. DAPI stain was used to visualize the
cell nuclei (blue). D: Quantification of the number of cytoplasmic protru-
sions from the captured fluorescent images. Results shown represent the
mean ± SEM over fifteen fields of view (*p < 0.05). E: Relative cell adhesion
in CaSki EGFP and Kpnβ1-EGFP cells. Adherent cells were fixed (after
removing non-adherent cells by washing) and stained with 0.5% crystal
violet solution. Cells over ten fields of view, viewed at 10 x magnification,
were counted using ImageJ and normalized to unwashed cells. Results
shown represent the mean ± SEM (*p < 0.05). F: Western blot analysis was
used to determine the expression levels of E-cadherin and Vimentin in
CaSki Kpnβ1-overexpressing cells. GAPDH was used as a control for load-
ing. G: An in vitro scratch wound healing assay was performed and
showed no change in migration of CaSki EGFP and Kpnβ1-EGFP cells
within a 24 h period. H: Quantification of the scratch wound healing
assay in G. (PPTX 627 kb)
Additional file 2: Figure S2. Overexpression of Kpnβ1 results in
increased sensitivity to Cisplatin. Dose-response curves are shown after
treatment of HeLa EGFP- and HeLa Kpnβ1-EGF-expressing cells with
Cisplatin. (PPTX 42 kb)
Additional file 3: Figure S3. p53 and p21 inhibition reduces and
enhances CaSki EGFP and Kpnβ1-EGFP cell sensitivity to Cisplatin, respect-
ively. A: CaSki EGFP (a) and Kpnβ1-EGFP (b) cells were co-treated with
Cisplatin and the p53 inhibitor Pifithrin α, and cell proliferation monitored
24 h later using the MTT assay. B: CaSki EGFP (a) and Kpnβ1-EGFP (b)
cells were transfected with control (ctl) or p21 siRNA, and 48 h later
treated with Cisplatin for 24 h, whereafter cell proliferation was
monitored using the MTT assay. Results shown represent the mean ±
SEM of experiments (*p < 0.05). (PPTX 59 kb)
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